MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Novartis AG

Uždarymo kaina

109.52 -1.67

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

109.36

Max

112.37

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-369M

2.8B

Pardavimai

386M

14B

P/E

Sektoriaus vid.

18.925

73.239

Pelnas, tenkantis vienai akcijai

1.98

Dividendų pajamingumas

3.48

Pelno marža

20.8

Darbuotojai

75,883

EBITDA

-426M

5.2B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-0.43% downside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.48%

3.06%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.4B

219B

Ankstesnė atidarymo kaina

111.19

Ankstesnė uždarymo kaina

109.52

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Novartis AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-11 06:57; UTC

Įsigijimai, susijungimai, perėmimai

Novartis to Buy Anthos Therapeutics for Up to $3.08 Billion

2025-01-31 09:49; UTC

Uždarbis

Novartis Expects Further Profit, Sales Growth Despite Competition Threat -- 2nd Update

2025-01-31 08:06; UTC

Uždarbis

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales -- Update

2025-01-31 06:32; UTC

Uždarbis

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales

2025-03-17 07:34; UTC

Rinkos pokalbiai

Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk

2025-03-04 18:45; UTC

Uždarbis

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction -- IBD

2025-02-11 09:25; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion -- Update

2025-02-11 06:42; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Novartis to Buy Anthos Therapeutics for Up to $3.08 Bln

2025-02-11 06:22; UTC

Įsigijimai, susijungimai, perėmimai

Novartis: Acquisition Is Aligned With Strategic Focus on Cardiovascular Therapeutic Area

2025-02-11 06:20; UTC

Įsigijimai, susijungimai, perėmimai

Novartis: Abelacimab's Lead Indication Is Prevention of Stroke, Systemic Embolism

2025-02-11 06:19; UTC

Įsigijimai, susijungimai, perėmimai

Novartis: Anthos Is Developing Abelacimab, Currently in Late-Stage Trials

2025-02-11 06:18; UTC

Įsigijimai, susijungimai, perėmimai

Novartis: Deal Is Expected to Close in 1H of 2025

2025-02-11 06:18; UTC

Įsigijimai, susijungimai, perėmimai

Novartis Aims to Bolster Late-Stage Cardiovascular Pipeline With Acquisition

2025-02-11 06:17; UTC

Įsigijimai, susijungimai, perėmimai

Novartis: Deal Includes Potential Additional Payments of Up to $2.15B

2025-02-11 06:16; UTC

Įsigijimai, susijungimai, perėmimai

Novartis to Buy Anthos Therapeutics for $925M Upfront

2025-02-11 06:15; UTC

Įsigijimai, susijungimai, perėmimai

Novartis to Buy Anthos Therapeutics

2025-02-04 15:16; UTC

Svarbiausios naujienos

Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says -- Interview

2025-02-04 08:12; UTC

Rinkos pokalbiai
Uždarbis

Novartis Outlook Indicates No Patent Cliff Beyond 2025 -- Market Talk

2025-01-31 13:56; UTC

Uždarbis

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker -- IBD

2025-01-31 09:59; UTC

Karštos akcijos

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

2025-01-31 07:50; UTC

Rinkos pokalbiai

Novartis's Outlook Exceeds Market Views -- Market Talk

2025-01-31 07:46; UTC

Rinkos pokalbiai
Uždarbis

Novartis's Results Beat Could Clear Gap Between Mid-Term Outlook and Market Views -- Market Talk

2025-01-31 06:03; UTC

Uždarbis

Novartis Expects 2025 Core Operating Profit Growth of High Single to Low Double-Digit at Constant Currency

2025-01-31 06:02; UTC

Uždarbis

Novartis Expects 2025 Net Sales Growth of mid- to high-single Digit at Constant Currency

2025-01-31 06:02; UTC

Uždarbis

Novartis Issues 2025 View

2025-01-31 06:02; UTC

Uždarbis

Novartis Raises Dividend to CHF3.50 Vs CHF3.30

2025-01-31 06:02; UTC

Uždarbis

Novartis 4Q Oper Pft $3.53B

2025-01-31 06:02; UTC

Uždarbis

Novartis 4Q Net Pft $2.82B

2025-01-31 06:02; UTC

Uždarbis

Analysts Saw Novartis 4Q Core Operating Profit at $4.44B

2025-01-31 06:02; UTC

Uždarbis

Novartis 4Q Core Operating Profit $4.86B

Akcijų palyginimas

Kainos pokytis

Novartis AG Prognozė

Kainos tikslas

By TipRanks

-0.43% į apačią

12 mėnesių prognozė

Vidutinis 111 USD  -0.43%

Aukščiausias 125 USD

Žemiausias 97 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Novartis AG kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

2 ratings

0

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

108.6463 / 111.415Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.